Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Short Interest Update

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) was the target of a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 21,880,000 shares, an increase of 39.6% from the November 30th total of 15,670,000 shares. Based on an average daily volume of 4,270,000 shares, the days-to-cover ratio is presently 5.1 days.

Taysha Gene Therapies Trading Down 5.9 %

Shares of TSHA stock traded down $0.11 on Friday, reaching $1.75. 1,600,983 shares of the stock were exchanged, compared to its average volume of 2,845,679. The stock has a 50 day moving average price of $2.12 and a 200 day moving average price of $2.24. The stock has a market cap of $358.65 million, a PE ratio of 2.78 and a beta of 0.79. Taysha Gene Therapies has a one year low of $1.19 and a one year high of $4.32. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51.

Wall Street Analyst Weigh In

TSHA has been the topic of a number of recent analyst reports. Cantor Fitzgerald restated an “overweight” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Needham & Company LLC reissued a “buy” rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. JMP Securities reaffirmed a “market outperform” rating and set a $5.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Chardan Capital reissued a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, November 14th. Finally, Canaccord Genuity Group raised their target price on Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Friday, November 15th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $6.63.

Institutional Trading of Taysha Gene Therapies

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp acquired a new stake in shares of Taysha Gene Therapies during the 2nd quarter worth approximately $1,018,000. Principal Financial Group Inc. bought a new stake in shares of Taysha Gene Therapies during the 2nd quarter valued at $48,000. Privium Fund Management B.V. acquired a new position in shares of Taysha Gene Therapies in the 2nd quarter valued at $213,000. Rhumbline Advisers bought a new stake in Taysha Gene Therapies in the second quarter valued at about $413,000. Finally, The Manufacturers Life Insurance Company lifted its stake in Taysha Gene Therapies by 109.0% in the second quarter. The Manufacturers Life Insurance Company now owns 133,213 shares of the company’s stock valued at $298,000 after buying an additional 69,487 shares during the period. 77.70% of the stock is owned by institutional investors.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.